MC225A7 - 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha - Google Patents
2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alphaInfo
- Publication number
- MC225A7 MC225A7 MC225K MC225K MC225A7 MC 225 A7 MC225 A7 MC 225A7 MC 225 K MC225 K MC 225K MC 225 K MC225 K MC 225K MC 225 A7 MC225 A7 MC 225A7
- Authority
- MC
- Monaco
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl
- dioxopiperidin
- indolines
- Prior art date
Links
- FPNJYPLJTAYAMP-UHFFFAOYSA-N 7a-(2,6-dioxopiperidin-3-yl)-3ah-isoindole-1,3-dione Chemical class C1=CC=CC2C(=O)NC(=O)C21C1CCC(=O)NC1=O FPNJYPLJTAYAMP-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- -1 m -phenylene Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4827897P | 1997-05-30 | 1997-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MC225A7 true MC225A7 (fr) | 2006-03-07 |
Family
ID=21953674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MC225K MC225A7 (fr) | 1997-05-30 | 2005-08-11 | 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha |
Country Status (25)
Country | Link |
---|---|
US (3) | US6395754B1 (hu) |
EP (3) | EP1486496B1 (hu) |
JP (2) | JP4307567B2 (hu) |
KR (1) | KR100526212B1 (hu) |
CN (3) | CN1911927A (hu) |
AT (2) | ATE401319T1 (hu) |
AU (1) | AU741982B2 (hu) |
CA (2) | CA2291218C (hu) |
CY (1) | CY1108348T1 (hu) |
CZ (1) | CZ299812B6 (hu) |
DE (2) | DE69825994T2 (hu) |
DK (2) | DK0984955T3 (hu) |
ES (3) | ES2403102T3 (hu) |
FI (1) | FI19992490A (hu) |
HK (1) | HK1072248A1 (hu) |
HU (2) | HU228769B1 (hu) |
MC (1) | MC225A7 (hu) |
NO (6) | NO322080B1 (hu) |
NZ (1) | NZ501429A (hu) |
PL (1) | PL193276B1 (hu) |
PT (2) | PT1486496E (hu) |
RU (1) | RU2209207C2 (hu) |
SK (1) | SK163099A3 (hu) |
TR (4) | TR200000107T2 (hu) |
WO (1) | WO1998054170A1 (hu) |
Families Citing this family (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
SK7382000A3 (en) * | 1997-11-18 | 2000-12-11 | Celgene Corp | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use |
CN100390163C (zh) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
ES2250121T3 (es) | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias. |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
JP2005536189A (ja) * | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
CN1697655B (zh) | 2002-05-17 | 2013-09-18 | 细胞基因公司 | 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物 |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
AU2003286663B2 (en) * | 2002-10-24 | 2009-08-13 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
NZ540186A (en) * | 2002-10-31 | 2008-03-28 | Celgene Corp | Composition for the treatment of macular degeneration |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
MXPA05004780A (es) | 2002-11-06 | 2005-10-05 | Celgene Corp | Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos. |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
JP2006510617A (ja) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | (+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物 |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
EA200600921A1 (ru) * | 2003-11-06 | 2006-10-27 | Селджин Корпорейшн | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний |
EP2065383A1 (en) | 2003-11-19 | 2009-06-03 | Signal Pharmaceuticals, Inc. | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
NZ550026A (en) * | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0418742A (pt) * | 2004-04-14 | 2007-09-11 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
JP2007532642A (ja) * | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物 |
CA2563810A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2005112928A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
ZA200702382B (en) * | 2004-09-03 | 2008-08-27 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines |
BRPI0518062A (pt) * | 2004-10-28 | 2008-10-28 | Celgene Corp | uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
US20060122228A1 (en) * | 2004-11-23 | 2006-06-08 | Zeldis Jerome B | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
BRPI0607239A2 (pt) * | 2005-01-25 | 2009-08-25 | Celgene Corp | usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples |
CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物 |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
CA2613548A1 (en) * | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
CA2612612C (en) | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US20070021762A1 (en) * | 2005-07-13 | 2007-01-25 | Qing Liu | Ocular plug formed from placenta derived collagen biofabric |
EP1919500A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
KR20080042158A (ko) | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
ES2359162T3 (es) | 2005-09-01 | 2011-05-19 | Celgene Corporation | Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
MX343814B (es) | 2005-10-13 | 2016-11-24 | Anthrogenesis Corp | Inmunomodulación usando celulas madre de la placenta. |
KR20080097190A (ko) * | 2005-12-29 | 2008-11-04 | 안트로제네시스 코포레이션 | 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
RU2448101C2 (ru) * | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
MX2009001989A (es) * | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
PL2420498T3 (pl) | 2006-09-26 | 2017-10-31 | Celgene Corp | 5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
WO2008057162A2 (en) | 2006-10-06 | 2008-05-15 | Anthrogenesis Corporation | Native (telopeptide) placental collagen compositions |
CN101186611B (zh) | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
NZ612888A (en) | 2007-02-12 | 2015-02-27 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
JP2010518812A (ja) * | 2007-02-12 | 2010-06-03 | アンスロジェネシス コーポレーション | 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにcd34+、cd45−胎盤幹細胞の濃縮細胞集団 |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
CN101952272B (zh) | 2007-09-26 | 2014-08-27 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
KR20210022148A (ko) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
SI2358697T1 (sl) | 2008-10-29 | 2016-02-29 | Celgene Corporation | Spojine izoindolina za uporabo pri zdravljenju raka |
WO2010093434A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of lenalidomide |
EP3489352A1 (en) | 2009-03-25 | 2019-05-29 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
ES2728776T3 (es) | 2009-05-19 | 2019-10-28 | Celgene Corp | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona |
EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CA2783616A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
CA2786266A1 (en) | 2010-01-05 | 2011-07-14 | Celgene Corporation | A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer |
EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US8853175B2 (en) | 2011-01-10 | 2014-10-07 | Celgene Corporation | Phenethylsulfone isoindoline derivatives and their use |
PE20140983A1 (es) | 2011-03-11 | 2014-08-25 | Celgene Corp | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
MX2013012083A (es) | 2011-04-18 | 2014-04-16 | Celgene Corp | Biomarcadores para el tratamiento de mieloma multiple. |
KR20140024914A (ko) | 2011-04-29 | 2014-03-03 | 셀진 코포레이션 | 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법 |
WO2012166844A2 (en) | 2011-06-01 | 2012-12-06 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
MX356105B (es) | 2011-09-14 | 2018-05-14 | Celgene Corp | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. |
HUE050327T2 (hu) | 2011-12-27 | 2020-11-30 | Amgen Europe Gmbh | Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal |
WO2013182660A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
ES2755748T3 (es) | 2012-07-27 | 2020-04-23 | Celgene Corp | Procedimientos para preparar compuestos de isoindolin-1,3-diona |
AU2013299631B2 (en) | 2012-08-09 | 2017-09-28 | Celgene Corporation | Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
EA201590535A1 (ru) | 2012-09-10 | 2015-07-30 | Селджин Корпорейшн | Способы лечения локально прогрессирующего запущенного рака молочной железы |
WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014254056B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
RS64038B1 (sr) | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
RU2695521C9 (ru) | 2014-10-30 | 2019-08-19 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
SI3313818T1 (sl) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
ITUB20169994A1 (it) | 2016-01-14 | 2017-07-14 | Phf Sa | Nuove forme cristalline di farmaci immunomodulatori |
BR112019011025A2 (pt) | 2016-12-03 | 2019-10-08 | Juno Therapeutics Inc | métodos para modulação de células t car |
PT3618842T (pt) | 2017-05-01 | 2024-01-12 | Juno Therapeutics Inc | Combinação de uma terapia celular e de um composto imunomodulador |
US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
MX2019015155A (es) | 2017-06-29 | 2020-08-03 | Juno Therapeutics Inc | Modelo de raton para valorar toxicidades asociadas con inmunoterapias. |
US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
US12006356B2 (en) | 2017-12-15 | 2024-06-11 | Juno Therapeutics, Inc. | Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same |
CA3092037A1 (en) | 2018-02-21 | 2019-08-29 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 |
CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
EP3880669A1 (en) | 2018-11-13 | 2021-09-22 | Biotheryx, Inc. | Substituted isoindolinones |
BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
US20220088070A1 (en) | 2018-11-30 | 2022-03-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
JP7494181B2 (ja) | 2018-12-19 | 2024-06-03 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
EP3917570A1 (en) | 2019-01-29 | 2021-12-08 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3378763D1 (en) * | 1982-04-02 | 1989-02-02 | Takeda Chemical Industries Ltd | Condensed pyrrolinone derivatives, and their production |
CA1284647C (en) * | 1986-12-25 | 1991-06-04 | Kazuhiro Kubo | Isoindolin-1-one derivative and anti-arrhythmic agent |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
ES2098505T3 (es) * | 1991-04-17 | 1997-05-01 | Gruenenthal Chemie | Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
DE4422237A1 (de) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
US5795368A (en) * | 1996-03-01 | 1998-08-18 | O.I. Corporation | Microtrap sample concentrator and methods of use |
DE19613976C1 (de) * | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
DE69717831T3 (de) * | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
DE69720735T9 (de) * | 1996-08-12 | 2005-08-25 | Celgene Corp. | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
ATE305301T1 (de) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
CN100390163C (zh) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
EP1165516B1 (en) * | 1999-03-12 | 2004-10-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
ES2250121T3 (es) * | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias. |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
MXPA02009665A (es) * | 2000-03-31 | 2005-09-08 | Celgene Corp | Inhibicion de actividad de ciclooxigenasa-2. |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
JP4494013B2 (ja) | 2001-08-06 | 2010-06-30 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
JP2005536189A (ja) | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法 |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN1697655B (zh) | 2002-05-17 | 2013-09-18 | 细胞基因公司 | 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物 |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
AU2003286663B2 (en) | 2002-10-24 | 2009-08-13 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
NZ540186A (en) | 2002-10-31 | 2008-03-28 | Celgene Corp | Composition for the treatment of macular degeneration |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
NZ548049A (en) * | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
NZ550026A (en) | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0418742A (pt) | 2004-04-14 | 2007-09-11 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
CA2563810A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2005112928A1 (en) | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
-
1997
- 1997-07-24 HU HU9903929A patent/HU228769B1/hu active Protection Beyond IP Right Term
-
1998
- 1998-05-28 CN CNA2006101262647A patent/CN1911927A/zh active Pending
- 1998-05-28 TR TR200000107T patent/TR200000107T2/xx unknown
- 1998-05-28 PL PL337124A patent/PL193276B1/pl unknown
- 1998-05-28 DE DE1998625994 patent/DE69825994T2/de not_active Expired - Lifetime
- 1998-05-28 ES ES08009864T patent/ES2403102T3/es not_active Expired - Lifetime
- 1998-05-28 CA CA 2291218 patent/CA2291218C/en not_active Expired - Fee Related
- 1998-05-28 ES ES04077432T patent/ES2309443T3/es not_active Expired - Lifetime
- 1998-05-28 DK DK98924959T patent/DK0984955T3/da active
- 1998-05-28 CN CN98805614A patent/CN1258293A/zh active Pending
- 1998-05-28 PT PT04077432T patent/PT1486496E/pt unknown
- 1998-05-28 SK SK1630-99A patent/SK163099A3/sk unknown
- 1998-05-28 CN CNA2005100525903A patent/CN1680367A/zh active Pending
- 1998-05-28 EP EP20040077432 patent/EP1486496B1/en not_active Expired - Lifetime
- 1998-05-28 NZ NZ501429A patent/NZ501429A/en not_active IP Right Cessation
- 1998-05-28 AT AT04077432T patent/ATE401319T1/de active
- 1998-05-28 EP EP20080009864 patent/EP1956017B1/en not_active Expired - Lifetime
- 1998-05-28 PT PT98924959T patent/PT984955E/pt unknown
- 1998-05-28 TR TR200500299T patent/TR200500299T2/xx unknown
- 1998-05-28 KR KR10-1999-7011076A patent/KR100526212B1/ko not_active IP Right Cessation
- 1998-05-28 AU AU77012/98A patent/AU741982B2/en not_active Ceased
- 1998-05-28 DE DE69839739T patent/DE69839739D1/de not_active Expired - Lifetime
- 1998-05-28 RU RU99128073A patent/RU2209207C2/ru not_active IP Right Cessation
- 1998-05-28 AT AT98924959T patent/ATE275139T1/de active
- 1998-05-28 EP EP19980924959 patent/EP0984955B1/en not_active Expired - Lifetime
- 1998-05-28 DK DK04077432T patent/DK1486496T3/da active
- 1998-05-28 TR TR201005282T patent/TR201005282T2/xx unknown
- 1998-05-28 HU HU0003217A patent/HU229578B1/hu not_active IP Right Cessation
- 1998-05-28 CA CA 2669481 patent/CA2669481C/en not_active Expired - Fee Related
- 1998-05-28 CZ CZ0427899A patent/CZ299812B6/cs not_active IP Right Cessation
- 1998-05-28 TR TR200801878T patent/TR200801878T2/xx unknown
- 1998-05-28 WO PCT/US1998/010886 patent/WO1998054170A1/en active Application Filing
- 1998-05-28 ES ES98924959T patent/ES2229497T3/es not_active Expired - Lifetime
- 1998-05-28 US US09/445,002 patent/US6395754B1/en not_active Expired - Lifetime
- 1998-05-28 JP JP50090999A patent/JP4307567B2/ja not_active Expired - Fee Related
-
1999
- 1999-11-23 NO NO19995751A patent/NO322080B1/no not_active IP Right Cessation
- 1999-11-23 FI FI992490A patent/FI19992490A/fi unknown
-
2002
- 2002-05-10 US US10/143,416 patent/US20020173658A1/en not_active Abandoned
-
2005
- 2005-01-14 US US11/035,817 patent/US7459466B2/en not_active Expired - Fee Related
- 2005-03-08 HK HK05102027A patent/HK1072248A1/xx not_active IP Right Cessation
- 2005-08-11 MC MC225K patent/MC225A7/xx unknown
-
2006
- 2006-03-30 NO NO20061455A patent/NO331367B1/no not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY081101005T patent/CY1108348T1/el unknown
-
2009
- 2009-02-06 JP JP2009025981A patent/JP2009138009A/ja active Pending
- 2009-08-18 NO NO20092860A patent/NO332270B1/no not_active IP Right Cessation
-
2011
- 2011-11-08 NO NO20111536A patent/NO332271B1/no not_active IP Right Cessation
-
2012
- 2012-03-06 NO NO2012004C patent/NO2012004I2/no unknown
- 2012-03-20 NO NO20120330A patent/NO333641B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MC225A7 (fr) | 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha | |
HK1049004A1 (zh) | 含氮的環狀化合物和含有該化合物的藥用組合物 | |
ATE164575T1 (de) | Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer | |
SE0000772D0 (sv) | Chemical compounds | |
DE69332792T2 (de) | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide | |
HK1072770A1 (en) | Bicyclic compound | |
EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
NO972887L (no) | Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel | |
AU633408B2 (en) | New imidazo (1,2-c) derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
DK0494816T3 (da) | Afledede af 1,4-dihydropyridin, fremgangsmåde til fremstilling heraf og terapeutisk sammensætning indeholdende disse | |
DK0412058T3 (da) | 1-Acyl-2-pyrrolidinoner som indlærings- og hukommelsesforstærkende midler og farmaceutiske præparater indeholdende disse forbindelser | |
EA200101109A1 (ru) | Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана | |
TW350835B (en) | Process for preparing nitroaniline derivatives | |
SE8800863D0 (sv) | 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith | |
EP1120415A4 (en) | SUBSTITUTED ISOXAZOLYLTHIOPHENE COMPOUNDS | |
MY133207A (en) | Substituted benzolactam compaunds | |
ATE66475T1 (de) | Aromatische thioaether. | |
ATE500241T1 (de) | Phenyl- und pyridyl-piperidine mit tnf-wirkung | |
ES2107376A1 (es) | Nuevos derivados de pirimidona con actividad antifungica. |